Silence Therapeutics Finishes Dosing 48 Patients in Blood Disorder Trial
Silence Therapeutics reported completing dosing of 48 polycythemia vera patients in its Phase 2 SANRECO double-blind, placebo-controlled trial of divesiran (6 mg/kg Q6W and Q12W) in June 2026, and presenting follow-up Phase 1 data at EHA 2026. The company reported Q2 2026 cash of $72.1 million and net loss of $12.3 million ($0.19 per share).
How this was made
The 30-second read
Why it matters
The key new operational milestone is completion of dosing in the Phase 2 SANRECO trial (48 phlebotomy-dependent PV patients), which can shift expectations for upcoming data and regulatory planning. The release also reiterates pipeline progress (SLN312 Phase 1 under AstraZeneca, preclinical IND positioning for 2027).
Market read
For traders, the actionable item is the Phase 2 dosing completion milestone, which can improve sentiment and set up the next data-driven inflection point, while the excerpt lacks hard topline timing or endpoint results.
What to watch
The release includes financials with cash and expense changes, but the excerpt does not provide updated guidance or a clear catalyst timeline for SANRECO topline, which can limit follow-through.
Background
Silence Therapeutics is a clinical-stage siRNA biotech advancing divesiran for polycythemia vera (PV) and other siRNA programs under collaborations.
Ticker impact
Silence Therapeutics completed dosing 48 PV patients in its Phase 2 SANRECO double-blind trial for divesiran, a direct clinical catalyst.
Shares may see a positive bias into the next trial readout window, but magnitude likely depends on whether topline efficacy/safety data are imminent.
The article discloses a concrete trial milestone (Phase 2 dosing completion) plus conference/published data references, which typically improves sentiment and optionality, though it does not provide efficacy endpoints or timing for topline results.
Market effects
Adds incremental momentum to siRNA biotech sentiment, particularly in hematology indications (PV) and lipid targets via ANGPTL3.
Primarily US-listed biotech sentiment, with European congress/publishing touchpoints.
Supports global clinical-development narratives for gene-silencing platforms, but no cross-border regulatory decision is disclosed.
Counterpoint
Dosing completion alone may not move the stock materially without quantified efficacy/safety outcomes or a specific topline date.
Key entities
- companySilence Therapeutics
Subject of the press release, reporting SANRECO dosing completion and Q2 2026 financial results.
- product_candidatedivesiran
First-in-class siRNA targeting TMPRSS6 for PV; Phase 2 SANRECO dosing completed.
- clinical_trialSANRECO
Phase 2 double-blind, placebo-controlled PV trial evaluating divesiran 6 mg/kg at Q6W and Q12W intervals.
- product_candidateSLN312 (AZD1705)
Phase 1 siRNA silencing ANGPTL3 program under an AstraZeneca collaboration; conference presentation referenced.